Pacira BioSciences (PCRX)
(Real Time Quote from BATS)
$20.63 USD
-0.12 (-0.58%)
Updated Aug 2, 2024 10:50 AM ET
3-Hold of 5 3
A Value C Growth F Momentum B VGM
Price, Consensus and EPS Surprise
PCRX 20.63 -0.12(-0.58%)
Will PCRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PCRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PCRX
Pacira (PCRX) Q2 Earnings Beat, Exparel Sales Drive Revenues
Pacira (PCRX) Reports Q2 Earnings: What Key Metrics Have to Say
PCRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates
Should Value Investors Buy Pacira BioSciences (PCRX) Stock?
Pacira (PCRX) Rises on Proposed Exparel Reimbursement Plan
Other News for PCRX
Pacira price target lowered by $4 at Raymond James, here's why
Pacira price target lowered by $5 at RBC Capital, here's why
Analysts Are Bullish on These Healthcare Stocks: Pacira Pharmaceuticals (PCRX), Definitive Healthcare Corp (DH)
Pacira Pharmaceuticals (PCRX) Gets a Buy from Piper Sandler
RBC Capital Keeps Their Buy Rating on Pacira Pharmaceuticals (PCRX)